Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALKi-Naïve Patients With ALK-Rearranged Non-Small-Cell Lung Cancer.

Nishio M, Felip E, Orlov S, Park K, Yu CJ, Tsai CM, Cobo M, McKeage M, Su WC, Mok T, Scagliotti GV, Spigel DR, Viraswami-Appanna K, Chen Z, Passos VQ, Shaw AT.

J Thorac Oncol. 2019 Nov 25. pii: S1556-0864(19)33660-3. doi: 10.1016/j.jtho.2019.11.006. [Epub ahead of print]

2.

Micropropagation of Solanum quitoense var. quitoense by apical bud, petiole and hypocotyl culture.

Gutiérrez B, Cobo MM, Orellana M, Vega J, Arahana V, Jaramillo V, Torres ML.

Plant Biotechnol (Tokyo). 2019;36(2):91-97. doi: 10.5511/plantbiotechnology.19.0317a.

3.

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators.

N Engl J Med. 2019 Nov 21. doi: 10.1056/NEJMoa1913662. [Epub ahead of print]

PMID:
31751012
4.

Brief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA.

Brown H, Vansteenkiste J, Nakagawa K, Cobo M, John T, Barker C, Kohlmann A, Todd A, Saggese M, Chmielecki J, Markovets A, Scott M, Ramalingam SS.

J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33334-9. doi: 10.1016/j.jtho.2019.09.009. [Epub ahead of print]

5.

Photodynamic therapy in endodontic root canal treatment significantly increases bacterial clearance, preventing apical periodontitis.

Zorita-García M, Alonso-Ezpeleta LÓ, Cobo M, Del Campo R, Rico-Romano C, Mena-Álvarez J, Zubizarreta-Macho Á.

Quintessence Int. 2019;50(10):782-789. doi: 10.3290/j.qi.a43249.

PMID:
31559398
6.

A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.

Villaruz LC, Cobo M, Syrigos K, Mavroudis D, Zhang W, Kim JS, Socinski MA.

Lung Cancer. 2019 Oct;136:52-56. doi: 10.1016/j.lungcan.2019.08.009. Epub 2019 Aug 14.

PMID:
31445354
7.

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Gray JE, Okamoto I, Sriuranpong V, Vansteenkiste J, Imamura F, Lee JS, Pang YK, Cobo M, Kasahara K, Cheng Y, Nogami N, Cho EK, Su WC, Zhang G, Huang X, Li-Sucholeiki X, Lentrichia B, Dearden S, Jenkins S, Saggese M, Rukazenkov Y, Ramalingam SS.

Clin Cancer Res. 2019 Nov 15;25(22):6644-6652. doi: 10.1158/1078-0432.CCR-19-1126. Epub 2019 Aug 22.

PMID:
31439584
8.

Controlling sugarcane press-mud fermentation to increase bioethanol steam reforming for hydrogen production.

Sanchez N, Ruiz RY, Cifuentes B, Cobo M.

Waste Manag. 2019 Oct;98:1-13. doi: 10.1016/j.wasman.2019.08.006. Epub 2019 Aug 13.

PMID:
31421484
9.

Prenatal gunshot wound, a rare cause of maternal and fetus trauma, a case report.

Molina GA, Aguayo WG, Cevallos JM, Gálvez PF, Calispa JF, Arroyo KA, Guzmán LJ, Cobo MM, Gutierrez BM, Toapanta RT, Briceño MM.

Int J Surg Case Rep. 2019;59:201-204. doi: 10.1016/j.ijscr.2019.05.034. Epub 2019 May 28.

10.

Whole-genome sequencing reveals nosocomial Clostridioides difficile transmission and a previously unsuspected epidemic scenario.

García-Fernández S, Frentrup M, Steglich M, Gonzaga A, Cobo M, López-Fresneña N, Cobo J, Morosini MI, Cantón R, Del Campo R, Nübel U.

Sci Rep. 2019 May 6;9(1):6959. doi: 10.1038/s41598-019-43464-4.

11.

Production Trends, Collaboration, and Main Topics of the Integrative and Complementary Oncology Research Area: A Bibliometric Analysis.

Moral-Munoz JA, Carballo-Costa L, Herrera-Viedma E, Cobo MJ.

Integr Cancer Ther. 2019 Jan-Dec;18:1534735419846401. doi: 10.1177/1534735419846401.

12.

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Sequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Adiwijaya B, Kuesters G, Kamoun WS, Andreas K, Pipas JM, Santillana S, Cho BC, Park K, Shepherd FA.

Oncologist. 2019 Aug;24(8):1095-1102. doi: 10.1634/theoncologist.2018-0695. Epub 2019 Apr 11.

PMID:
30975923
13.

Birth experience in newborn infants is associated with changes in nociceptive sensitivity.

Kasser S, Hartley C, Rickenbacher H, Klarer N, Depoorter A, Datta AN, Cobo MM, Goksan S, Hoskin A, Magerl W, Huhn EA, Green G, Slater R, Wellmann S.

Sci Rep. 2019 Mar 11;9(1):4117. doi: 10.1038/s41598-019-40650-2.

14.

Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors.

Nadal E, Massuti B, Dómine M, García-Campelo R, Cobo M, Felip E.

Cancer Immunol Immunother. 2019 Mar;68(3):341-352. doi: 10.1007/s00262-019-02310-2. Epub 2019 Feb 6. Review.

PMID:
30725206
15.

Stable Genetic Modification of Mesenchymal Stromal Cells Using Lentiviral Vectors.

Martín F, Tristán-Manzano M, Maldonado-Pérez N, Sánchez-Hernández S, Benabdellah K, Cobo M.

Methods Mol Biol. 2019;1937:267-280. doi: 10.1007/978-1-4939-9065-8_17.

PMID:
30706403
16.

Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.

von Pawel J, Bordoni R, Satouchi M, Fehrenbacher L, Cobo M, Han JY, Hida T, Moro-Sibilot D, Conkling P, Gandara DR, Rittmeyer A, Gandhi M, Yu W, Matheny C, Patel H, Sandler A, Ballinger M, Kowanetz M, Park K.

Eur J Cancer. 2019 Jan;107:124-132. doi: 10.1016/j.ejca.2018.11.020. Epub 2018 Dec 17.

PMID:
30562710
17.

Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.

Karachaliou N, Bracht JWP, Fernandez Bruno M, Drozdowskyj A, Gimenez Capitan A, Moran T, Carcereny E, Cobo M, Domine M, Chaib I, Ramirez JL, Camps C, Provencio M, Vergnenegre A, Lopez-Vivanco G, Majem M, Massuti B, Rosell R.

J Thorac Oncol. 2019 Feb;14(2):304-310. doi: 10.1016/j.jtho.2018.10.168. Epub 2018 Nov 22.

PMID:
30472259
18.

Duration of Treatment with Corticosteroids and Recovery of Kidney Function in Acute Interstitial Nephritis.

Fernandez-Juarez G, Perez JV, Caravaca-Fontán F, Quintana L, Shabaka A, Rodriguez E, Gadola L, de Lorenzo A, Cobo MA, Oliet A, Sierra M, Cobelo C, Iglesias E, Blasco M, Galeano C, Cordon A, Oliva J, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN).

Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1851-1858. doi: 10.2215/CJN.01390118. Epub 2018 Nov 5.

PMID:
30397027
19.

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).

Morgensztern D, Cobo M, Ponce Aix S, Postmus PE, Lewanski CR, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Fasola G, Ardizzoni A, Bhore R, Wolfsteiner M, Talbot DC, Jin Ong T, Govindan R, On Behalf Of The Abound L Investigators.

Cancer. 2018 Dec 15;124(24):4667-4675. doi: 10.1002/cncr.31779. Epub 2018 Nov 1.

PMID:
30383906
20.

Ascaris lumbricoides and its almost deadly complication.

Molina GA, Torres AR, Llerena PS, Yu A, Sánchez AC, Cobo MM.

J Surg Case Rep. 2018 Oct 5;2018(10):rjy262. doi: 10.1093/jscr/rjy262. eCollection 2018 Oct.

21.

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J.

J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118. [Epub ahead of print]

PMID:
30153097
22.

Increased Expression of Musashi-1 Evidences Mesenchymal Repair in Maxillary Sinus Floor Elevation.

O'Valle F, de Buitrago JG, Hernández-Cortés P, Padial-Molina M, Crespo-Lora V, Cobo M, Aguilar D, Galindo-Moreno P.

Sci Rep. 2018 Aug 16;8(1):12243. doi: 10.1038/s41598-018-29908-3.

23.

Searching for the best agent for antibiotic prophylaxis in patients undergoing transcatheter aortic valve implantation.

Ramos-Martinez A, Cobo M, Munez E, Restrepo A, Fernandez-Cruz A.

J Hosp Infect. 2018 Dec;100(4):458-459. doi: 10.1016/j.jhin.2018.07.020. Epub 2018 Jul 18. No abstract available.

PMID:
30031165
24.

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.

Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC.

JAMA Oncol. 2018 Sep 1;4(9):1189-1197. doi: 10.1001/jamaoncol.2018.0775.

25.

Smartphone Applications to Perform Body Balance Assessment: a Standardized Review.

Moral-Munoz JA, Esteban-Moreno B, Herrera-Viedma E, Cobo MJ, Pérez IJ.

J Med Syst. 2018 May 29;42(7):119. doi: 10.1007/s10916-018-0970-1. Review.

PMID:
29845455
26.

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.

Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S, Han JY, Gadgeel SM, Hida T, Cortinovis DL, Cobo M, Kowalski DM, De Marinis F, Gandhi M, Danner B, Matheny C, Kowanetz M, He P, Felizzi F, Patel H, Sandler A, Ballinger M, Barlesi F.

J Thorac Oncol. 2018 Aug;13(8):1156-1170. doi: 10.1016/j.jtho.2018.04.039. Epub 2018 May 17. Erratum in: J Thorac Oncol. 2018 Nov;13(11):1800.

27.

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).

Forster M, Hackshaw A, De Pas T, Cobo M, Garrido P, Summers Y, Dingemans AC, Flynn M, Schnell D, von Wangenheim U, Loembé AB, Kaiser R, Lee SM.

Lung Cancer. 2018 Jun;120:27-33. doi: 10.1016/j.lungcan.2018.03.007. Epub 2018 Mar 9.

28.

Editorial: Mapping microbiology with scientometrics - help provide a clearer vision of microbiology research around the globe.

Redfern J, Cobo MJ, Herrera-Viedma E.

FEMS Microbiol Lett. 2018 May 1;365(9). doi: 10.1093/femsle/fny061. No abstract available.

PMID:
29635342
29.

Clinical and Functional Characterization of a Missense ELF2 Variant in a CANVAS Family.

Ahmad H, Requena T, Frejo L, Cobo M, Gallego-Martinez A, Martin F, Lopez-Escamez JA, Bronstein AM.

Front Genet. 2018 Mar 23;9:85. doi: 10.3389/fgene.2018.00085. eCollection 2018.

30.

Prognostic implications of a negative echocardiography in patients with infective endocarditis.

Vicent L, Saldivar HG, Bouza E, Muñoz P, Cuerpo G, de Alarcón A, Vidal B, Cobo M, Goenaga MÁ, Carrasco-Chinchilla F, Montejo M, Gálvez-Acebal J, Hidalgo-Tenorio C, Vinuesa-García D, Martínez-Sellés M; GAMES investigators (Appendix 1).

Eur J Intern Med. 2018 Jun;52:40-48. doi: 10.1016/j.ejim.2018.01.033. Epub 2018 Feb 4.

PMID:
29409744
31.

Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis.

González-Larriba JL, Lázaro-Quintela M, Cobo M, Dómine M, Majem M, García-Campelo R.

Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S21-S34. doi: 10.21037/tlcr.2017.10.03. Review.

32.

Dipolar filtered magic-sandwich-echoes as a tool for probing molecular motions using time domain NMR.

Filgueiras JG, da Silva UB, Paro G, d'Eurydice MN, Cobo MF, deAzevedo ER.

J Magn Reson. 2017 Dec;285:47-54. doi: 10.1016/j.jmr.2017.10.008. Epub 2017 Oct 20.

PMID:
29102820
33.

Individual Patterns of Complexity in Cystic Fibrosis Lung Microbiota, Including Predator Bacteria, over a 1-Year Period.

de Dios Caballero J, Vida R, Cobo M, Máiz L, Suárez L, Galeano J, Baquero F, Cantón R, Del Campo R.

MBio. 2017 Sep 26;8(5). pii: e00959-17. doi: 10.1128/mBio.00959-17.

34.

Comparison of Zinc Finger Nucleases Versus CRISPR-Specific Nucleases for Genome Editing of the Wiskott-Aldrich Syndrome Locus.

Gutierrez-Guerrero A, Sanchez-Hernandez S, Galvani G, Pinedo-Gomez J, Martin-Guerra R, Sanchez-Gilabert A, Aguilar-González A, Cobo M, Gregory P, Holmes M, Benabdellah K, Martin F.

Hum Gene Ther. 2018 Mar;29(3):366-380. doi: 10.1089/hum.2017.047. Epub 2017 Oct 25.

PMID:
28922955
35.

Colonoscopy and Endocarditis: A Compromised Relationship.

Ramos-Martínez A, Cobo M, Restrepo A, Mucientes J, Orden Martínez B, Rodríguez-Alfonso B.

Rev Esp Cardiol (Engl Ed). 2018 Oct;71(10):862-864. doi: 10.1016/j.rec.2017.07.007. Epub 2017 Aug 8. English, Spanish. No abstract available.

PMID:
28800912
36.

The use of two-dimensional NMR relaxometry in bread staling: a valuable tool?

Curti E, Carini E, Cobo MF, Bocher T, Vittadini E.

Food Chem. 2017 Dec 15;237:766-772. doi: 10.1016/j.foodchem.2017.05.143. Epub 2017 Jun 8.

PMID:
28764065
37.

Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity.

Cobo M, Gutiérrez V, Villatoro R, Trigo JM, Ramos I, López O, Ruiz M, Godoy A, López I, Arroyo M.

Lung Cancer (Auckl). 2017 Jul 12;8:57-66. doi: 10.2147/LCTT.S118996. eCollection 2017. Review.

38.

Antibiotic resistance and population structure of cystic fibrosis Pseudomonas aeruginosa isolates from a Spanish multi-centre study.

López-Causapé C, de Dios-Caballero J, Cobo M, Escribano A, Asensio Ó, Oliver A, Del Campo R, Cantón R, Solé A, Cortell I, Asensio O, García G, Martínez MT, Cols M, Salcedo A, Vázquez C, Baranda F, Girón R, Quintana E, Delgado I, de Miguel MÁ, García M, Oliva C, Prados MC, Barrio MI, Pastor MD, Olveira C, de Gracia J, Álvarez A, Escribano A, Castillo S, Figuerola J, Togores B, Oliver A, López C, de Dios Caballero J, Tato M, Máiz L, Suárez L, Cantón R.

Int J Antimicrob Agents. 2017 Sep;50(3):334-341. doi: 10.1016/j.ijantimicag.2017.03.034. Epub 2017 Jul 20.

PMID:
28735882
39.

Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy.

Felip E, Hirsh V, Popat S, Cobo M, Fülöp A, Dayen C, Trigo JM, Gregg R, Waller CF, Soria JC, Goss GD, Gordon J, Wang B, Palmer M, Ehrnrooth E, Gadgeel SM.

Clin Lung Cancer. 2018 Jan;19(1):74-83.e11. doi: 10.1016/j.cllc.2017.06.002. Epub 2017 Jun 23.

40.

Evaluation of scientific output in Dentistry in Spanish Universities.

De la Flor-Martínez M, Galindo-Moreno P, Sánchez-Fernández E, Abadal E, Cobo MJ, Herrera-Viedma E.

Med Oral Patol Oral Cir Bucal. 2017 Jul 1;22(4):e491-e499.

41.

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.

Gadgeel S, Goss G, Soria JC, Felip E, Georgoulias V, Lu S, Cobo M, Syrigos K, Lee KH, Göker E, Guclu SZ, Isla D, Morabito A, Dupuis N, Bühnemann C, Krämer N, Solca F, Ehrnrooth E, Ardizzoni A.

Lung Cancer. 2017 Jul;109:101-108. doi: 10.1016/j.lungcan.2017.05.010. Epub 2017 May 11.

42.

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.

Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile DJ, Lawrence D, Bowen K, Vansteenkiste J.

JAMA. 2017 May 9;317(18):1844-1853. doi: 10.1001/jama.2017.3438.

43.

Antimicrobial-resistant Escherichia coli and Enterococcus spp. isolated from Miranda donkey (Equus asinus): an old problem from a new source with a different approach.

Carvalho I, Campo RD, Sousa M, Silva N, Carrola J, Marinho C, Santos T, Carvalho S, Nóvoa M, Quaresma M, Pereira JE, Cobo M, Igrejas G, Poeta P.

J Med Microbiol. 2017 Mar;66(2):191-202. doi: 10.1099/jmm.0.000423.

PMID:
28260587
44.

A consensus statement on the gender perspective in lung cancer.

Isla D, Majem M, Viñolas N, Artal A, Blasco A, Felip E, Garrido P, Remón J, Baquedano M, Borrás JM, Die Trill M, García-Campelo R, Juan O, León C, Lianes P, López-Ríos F, Molins L, Planchuelo MÁ, Cobo M, Paz-Ares L, Trigo JM, de Castro J.

Clin Transl Oncol. 2017 May;19(5):527-535. doi: 10.1007/s12094-016-1578-x. Epub 2016 Nov 24. Review.

PMID:
27885542
45.

Lent-On-Plus Lentiviral vectors for conditional expression in human stem cells.

Benabdellah K, Muñoz P, Cobo M, Gutierrez-Guerrero A, Sánchez-Hernández S, Garcia-Perez A, Anderson P, Carrillo-Gálvez AB, Toscano MG, Martin F.

Sci Rep. 2016 Nov 17;6:37289. doi: 10.1038/srep37289.

46.

Gut eradication of VIM-1 producing ST9 Klebsiella oxytoca after fecal microbiota transplantation for diarrhea caused by a Clostridium difficile hypervirulent R027 strain.

García-Fernández S, Morosini MI, Cobo M, Foruny JR, López-Sanromán A, Cobo J, Romero J, Cantón R, Del Campo R.

Diagn Microbiol Infect Dis. 2016 Dec;86(4):470-471. doi: 10.1016/j.diagmicrobio.2016.09.004. Epub 2016 Sep 16.

PMID:
27712927
48.

Microbial degradation, cytotoxicity and antibacterial activity of polyurethanes based on modified castor oil and polycaprolactone.

Uscátegui YL, Arévalo FR, Díaz LE, Cobo MI, Valero MF.

J Biomater Sci Polym Ed. 2016 Dec;27(18):1860-1879. doi: 10.1080/09205063.2016.1239948. Epub 2016 Oct 11.

PMID:
27654066
49.

[Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].

Cobo M, Gutiérrez V, Rodelo L, López O, Ruiz M, Godoy A.

Med Clin (Barc). 2016 Apr;146 Suppl 1:25-9. doi: 10.1016/S0025-7753(16)30260-3. Review. Spanish.

PMID:
27426245
50.

Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy.

De Castro J, González-Larriba JL, Vázquez S, Massutí B, Sanchez-Torres JM, Dómine M, Garrido P, Calles A, Artal A, Collado R, García R, Sereno M, Majem M, Macías JA, Juan O, Gómez-Codina J, Hernández B, Lázaro M, Ortega AL, Cobo M, Trigo JM, Carcereny E, Rolfo C, Macia S, Muñoz J, Diz P, Méndez M, Rosillo F, Paz-Ares L, Cardona JV, Isla D.

Clin Transl Oncol. 2017 Feb;19(2):219-226. doi: 10.1007/s12094-016-1527-8. Epub 2016 Jul 1.

PMID:
27371031

Supplemental Content

Support Center